Novartis Investigative Site

Hadera 3820302

2 studies enrolling now · 10 studies all time

What they study most

Acute Decompensated Heart Failure, Acute Heart Failure, Anemia, Iron-Deficiency, Chronic Heart Failure With Reduced Ejection Fraction, Congestive Heart Failure, Glomerulonephritis, IGA, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Immunoglobulin A Nephropathy, Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS)

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis — Recruiting now
• Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN — Recruiting now
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients — Completed
• A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients — Completed
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction — Completed
• Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure — Completed